
Donor stem cell therapy delays progression of osteoarthritis
New research by Australian biotechnology company Magellan Stem Cells has demonstrated potential therapeutic benefits of a stem cell therapy for osteoarthritis. The Phase I/II clinical trial assessed the safety and efficacy of MAG200, Magellan Stem Cells’ off-the-shelf allogeneic (donor) stem cell therapy for osteoarthritis of the… Read More
